- Risk and causes of paediatric hospital-acquired bacteraemia in Kilifi District Hospital, Kenya: a prospective cohort study
[作者:Aiken, AM; Mturi, N; Njuguna, P; Mohammed, S; Berkley, JA; Mwangi, I; Mwarumba, S; Kitsao, BS; Lowe, BS; Morpeth, SC; Hall, AJ; Khandawalla, I; Scott, JAG,期刊:Lancet, 页码:2021-2027 , 文章类型: Article,,卷期:2011年378-9808]
- Background In sub-Saharan Africa, community-acquired bacteraemia is an important cause of illness and death in children. Our aim was to establish the magnitude and causes of hospital-acquired (nosocomial) bacteraemia in ...
- Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20 536 high-risk individuals: a randomised controlled trial
[作者:Bulbulia, R; Bowman, L; Wallendszus, K; Parish, S; Armitage, J; Peto, R; Collins, R; Meade, T; Sleight, P; Armitage, J; Parish, S; Youngman, L; Buxton, M; de Bono, D; George, C; Fuller, J; Keech, A; Mansfi, A; Pentecost, B; Simpson, D; Warlow, C; McNamara, J; O'Toole, L; Doll, R; Wilhelmsen, L; Fox, KM; Hill, C; Sandercock, P,期刊:Lancet, 页码:2013-2020 , 文章类型: Article,,卷期:2011年378-9808]
- Background Findings of large randomised trials have shown that lowering LDL cholesterol with statins reduces vascular morbidity and mortality rapidly, but limited evidence exists about the long-term efficacy and safety o...
- Routine blood tests? Helping you live(r) longer!
[作者:Berardi, S; Berzigotti, A; Cappelli, A; Mastroroberto, M; Serra, C; D'Errico, A; Russo, V; Garcia-Criado, A; Sama, C,期刊:Lancet, 页码:2048-2048 , 文章类型: Editorial Material,,卷期:2011年378-9808]
-
- Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study
[作者:Pavel, ME; Hainsworth, JD; Baudin, E; Peeters, M; Horsch, D; Klimovsky, J; Lebwohl, D; Jehl, V; Wolin, EM; Oberg, K; Van Cutsem, E; Yao, JC,期刊:Lancet, 页码:2005-2012 , 文章类型: Article,,卷期:2011年378-9808]
- Background Everolimus, an oral inhibitor of the mammalian target of rapamycin (mTOR), has shown antitumour activity in patients with advanced pancreatic neuroendocrine tumours. We aimed to assess the combination of evero...
|